Status:

TERMINATED

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Lead Sponsor:

Tufts Medical Center

Collaborating Sponsors:

Partner Therapeutics, Inc.

Conditions:

Advanced Lung Non-Small Cell Carcinoma

Non-Small Cell Carcinoma of Lung, TNM Stage 4

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer...

Detailed Description

Lung cancer is the most commonly diagnosed cancer worldwide. Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of prog...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Histologically confirmed stage 4 NSCLC or stage 3B/3C not able to receive chemoradiation with no sensitizing EGFR or ALK mutations.
  • PDL-1 of 1%-49%
  • No previous history of immunotherapy treatment
  • ECOG PS 0-1
  • At least one measurable lesion according to RECIST version 1.1
  • Life expectancy of at least 3 months.
  • Able to self-administer daily GM-CSF injections
  • Eligible for treatment with 4 cycles of chemoimmunotherapy followed by maintenance therapy with pembrolizumab +/- pemetrexed.

Exclusion

  • Receiving systemic glucocorticoids or other immunosuppressive treatment
  • Untreated brain metastases
  • Active autoimmune disease
  • Active interstitial lung disease, pneumonitis
  • Solid organ transplant recipients
  • Subject may not participate in another drug research study while participating in this research study
  • Pregnant patients
  • Known hypersensitivity to GM-CSF (sargramostim)

Key Trial Info

Start Date :

January 3 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 6 2024

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT04856176

Start Date

January 3 2022

End Date

December 6 2024

Last Update

January 1 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tufts Medical Center

Boston, Massachusetts, United States, 02111

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | DecenTrialz